Related Experiment Video
Updated: May 23, 2026

Examination of Pyroptosis by Flow Cytometry
Published on: May 31, 2024
Pyroptosis, A Double-Edged Sword in Respiratory Diseases: A Narrative Review
Chen Yu1, Caijun Dai1, Lujian Zhu2
1Department of Respiratory and Critical Care Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, People's Republic of China.
Abstract:
Pyroptosis is an inflammatory form of programmed cell death (PCD) driven by the gasdermin protein family. This process begins when danger- or damage-associated molecular patterns (DAMPs) are recognized, triggering either the canonical Caspase-1 or non-canonical Caspase-4/5/11 pathways. These pathways activate the cleavage of gasdermin D (GSDMD), releasing N-terminal fragments that form pores in cell membranes. This pore formation increases membrane permeability, leading to cell swelling and eventual lytic rupture. Pyroptosis serves as a double-edged sword in innate immunity: it defends against pathogens but can cause excessive inflammation and tissue damage if dysregulated. Evidence suggests that pyroptosis is involved in various respiratory diseases. The roles of pyroptosis and the Gasdermin family are complex, often exhibiting dual effects that complicate clinical interpretations. This review explores the molecular mechanisms and regulatory networks of pyroptosis, focusing on recent findings related to its role in pulmonary infections, acute lung injury (ALI)/ acute respiratory distress syndrome (ARDS), allergic asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis (PF), and lung cancer. We also examine therapeutic strategies targeting pyroptotic pathways and recent advancements in their development, aiming to provide a theoretical foundation and new directions for mechanistic research and clinical translation in respiratory immune-inflammatory diseases.
Insights
Pyroptosis, an inflammatory cell death, involves gasdermin proteins and is implicated in respiratory diseases. Understanding pyroptosis mechanisms and targeting its pathways offers potential for treating lung conditions.
Area of Science:
- Immunology
- Cell Biology
- Pathology
Background:
- Pyroptosis is a programmed cell death (PCD) pathway mediated by gasdermin proteins.
- It is triggered by danger signals and involves caspase activation, leading to membrane pore formation and cell lysis.
- Dysregulated pyroptosis contributes to inflammation and tissue damage, particularly in respiratory diseases.
Purpose of the Study:
- To review the molecular mechanisms and regulatory networks of pyroptosis.
- To explore the role of pyroptosis in various respiratory diseases, including infections, ALI/ARDS, asthma, COPD, PF, and lung cancer.
- To examine therapeutic strategies targeting pyroptotic pathways for respiratory immune-inflammatory diseases.
Main Methods:
- Literature review of pyroptosis mechanisms and its involvement in respiratory pathologies.
- Analysis of recent findings on gasdermin family roles in disease.
- Examination of current and emerging therapeutic strategies targeting pyroptosis.
Main Results:
- Pyroptosis acts as a double-edged sword in innate immunity, defending against pathogens but causing damage when dysregulated.
- Evidence links pyroptosis to pulmonary infections, ALI/ARDS, asthma, COPD, PF, and lung cancer.
- Targeting pyroptotic pathways shows promise for therapeutic intervention.
Conclusions:
- Pyroptosis plays a complex and often dual role in respiratory immune-inflammatory diseases.
- Further research into pyroptosis mechanisms and Gasdermin family functions is crucial.
- Targeted therapies for pyroptosis offer potential for clinical translation in treating lung diseases.
Related Concept Videos
Pneumothorax II: Pathophysiology
Pneumonia II: Pathophysiology
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Atelectasis II: Pathophysiology
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Pneumonia I: Introduction
